Opiate treatment producer RB Pharmaceuticals to be spun off
Reckitt Benckiser will spin off its subsidiary RB Pharmaceuticals in a London listing in the next 12 months, the consumer goods producer said when it released its 2014 first half results on Monday.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts